Nephrology

Stay updated with the latest healthcare breakthroughs, including FDA news and the voluntary withdrawal of obeticholic acid, in this week's essential news roundup.

Garimella describes recent progress in renal xenotransplantation, uncertainties that still need to be addressed, and how he sees it impacting the field moving forward.

Upon further review of the sNDA, the Agency indicated an advisory committee for sparsentan in FSGS is no longer needed.

The first patient in the ongoing Multi-Patient Expanded Access study has surpassed 7 months kidney function, and a second patient has been successfully transplanted.

The death rate from high blood pressure-related kidney disease increased by 48% from 1999-2023, with notable disparities by race, ethnicity, sex, and region.

Salvatore Viscomi, MD, warns CKDu is a growing global health crisis, driven by heat stress, toxins, and occupational risks in vulnerable populations.

Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Vancomycin was linked to a higher risk of acute kidney injury than alternative antibiotics, underscoring the need for appropriate prevention strategies.

Stay updated with the latest healthcare breakthroughs, including FDA news, vaccine guidelines, and orforglipron data, in this week's essential news roundup.

Pergola breaks down findings from a phase 2 trial of OLC for managing hyperphosphatemia in patients with chronic kidney disease receiving dialysis.

The REMS label update reduces the frequency of liver function monitoring and removes the embryo-fetal toxicity monitoring requirement.

An audio recap of the top 5 stories in healthcare news from the week of 08/17-08/

Healthcare costs and resource utilization were significantly greater in individuals with ASCVD and CKD with systemic inflammation versus those without.

Hydroxychloroquine reduced proteinuria levels with an acceptable safety profile but had limited effects on overall eGFR in primary glomerular diseases.

An audio recap of the top 5 stories in healthcare news from the week of 08/10-08/16.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.

Stay updated with the latest healthcare breakthroughs, including FDA news and new guidelines, in this week's essential news roundup.

Stone clearance was similar with ureteroscopy vs shockwave lithotripsy, but the latter was associated with better recovery and patient-reported outcomes.

The global burden of CKD attributable to high BMI has shown a consistent upward trend from 1990 to 2021, with projections further increases by 2050.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

Check out the latest renal regulatory news, clinical trial data, and nephrology research in this July 2025 recap.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.

FDA approves pegcetacoplan (Empaveli) for treating C3 glomerulopathy and primary IC-MPGN, offering hope for patients aged 12 and older.